Insulin icodec is a novel, long-acting insulin analog designed for once-weekly administration that is in development for the treatment of diabetes. It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. In this touchENDOCRINOLOGY interview, Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) discusses how reduced frequency of dosing will improve adherence among patients. Prof. Chantal Mathieu also gives an update in the clinical development of insulin icodec the impact it will have on patient quality-of-life and clinical practice.
The abstract entitled: ‘Once Weekly Insulins: The Clinical Evidence to date’ was presented at the European Association for the Study of Diabetes, 19-23 Sept, 2022.
- What previous clinical evidence supports the use of once weekly insulin? (0:20)
- How will reduced frequency of dosing improve adherence and in turn glycaemic control? (1:27)
- Please could you give us an update on the clinical development of insulin icodec and basal insulin Fc (BIF)? (2:44)
- If approved, what will be the impact of once weekly insulin on patient quality-of-life and clinical practice? (5:37)
Disclosures: Chantal Mathieu discloses grant/research support from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of EASD 2022
Share this Video
Related Videos In Diabetes
Chantal Mathieu: Research highlights from 2022
We were delighted to speak with our editorial board member Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) around this year’s research highlights in diabetes and what to look out for in 2023. Questions What are the key clinical highlights from 2022 in the field of diabetes? (0:16) What are the hot topics and […]
José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials
In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of the Rocket AP will be. The abstract entitled: ‘RocketAP in Practice: Results from Pilot and Feasibility […]
José García-Tirado, DTM 2022: Challenges in the development of artificial pancreas systems
An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose in the body. In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) discusses the major challenges in the development of artificial pancreas systems. The abstract entitled: ‘RocketAP in Practice: Results from Pilot […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!